On Thursday, Gilead Sciences Inc says it expects to meet 'real-time global demand' for remdesivir by October and will produce two million treatment courses by the end of 2020.
Etiam at libero iaculis, mollis justo non, blandit augue. Vestibulum sit amet sodales est, a lacinia ex. Suspendisse vel enim sagittis, volutpat sem eget, condimentum sem.
0 comments: